Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
It will be conducted as an international multicenter prospective observational cohort study
in a population of ErbB2 positive metastatic breast cancer patients, whose disease has
progressed after trastuzumab-containing regimen, comparing outcomes in two groups: Group 1:
patients receiving Lapatinib-capecitabine immediately after 1st Trastuzumab progression
(second line treatment), and Group 2: patients receiving Lapatinib-capecitabine after 2 or
more lines of treatment after 1st trastuzumab progression (third line or greater).